1BURASHNIKOV A, ANTZELEVITCH C. New pharmacological strategies for the treatment of atrial fibrillation [ J ]. Ann Noninvasive Electrocardiol, 2009,14:290-300.
2NATTEI. S,CARI.SSON L. Innovative approaches to anti-arrhythmic drug therapy[J]. Nat Rev Drug Discoy, 2006,5:1034-49.
3FEDIDA D. The mechanism of atrial antiarrhythmic action of RSD1235[J]. J Cardiovasc Electrophysiol, 2005,16:1227-1238.
4DORIAN P. The effect of vernakalant (RSD1235), an investigational antiarrhythmie agent, on atrial electrophysiology in humans[J].J Cardiovasc Pharmacol, 2007,50:35-40.
5MAO Z L. Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection ( RSD1235 ) : influence of CYP2D6 expression and other factors[J]. J Clin Pharmacol, 2009,49:17 -29.
6WEEKE P. Vernakalant (RSD1235) in the management of atrial fibrillation: a review of pharmacological properties, clinical efficacy and safety[J]. Future Cardiol, 2008,4:559-567.
7ROY D. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation[J]. J Am Coll Cardiol, 2004,44:2355-2361.
8ROY D. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial[J].Circulation, 2008, 117: 1518-1525.
9KOWEY P R. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial [J].Circ Arrhythm Eleetrophysiol, 2009,2: 652- 659.
10PATEL C. Dronedarone[J]. Circulation, 2009, 120: 636-644.
4Anthony B, Gregory B, Cheu E, et al. Synthetic process for aminocyclohexyl ether compounds: WO, 2006 088525 EP]. 2006-08-24. (CA 2006, 145: 271413).
5Gregory B, Bertrand P, Ricgard W, et al. Aminocyclohexyl ether compounds and uses thereof: WO, 2004099137 [P]. 2004-11-18. (CA 2004, 141:424107).
6Anthony B, Lewis C. Synthetic process for trans- aminocyclohexyl ether compounds: WO, 2005016242 [P]. 2005 -02-24.
7Yaegashi K, Mikami M. Process for preparing amines: US, 2005222430 [P]. 2005-10-06. (CA2005, 141: 366997).
8Krishna L, Denise MF, Madeleine MJ. Synthetic routes to chiral 3-pyrrolidinols [J]. Synth Commun, 1985, 15 (7): 587-589.
9Sternfeld F, Guiblin AR, Jelley RA, et al. Synthesis and serotonergic activity of 3- E2- (pyrrolidin-l-yl) ethyl] indoles: potent agonists for the 5-HT,D receptor with high selectivity over the 5-HTIB receptor [J]. J Med Chem, 1999, 42 (4): 677-690.
10Anthony B, Gregory B, Cheu E, et al. Derivatives of ion channel modulating compounds and pharmaceutical compositions and uses thereof: WO, 2005094897 [P]. 2005-10-13. (CA 2005, 143: 367024).
